Literature DB >> 12861471

Fibromyalgia syndrome: an overview of potential drug targets.

Mike Briley1, Chantal Moret.   

Abstract

Fibromyalgia syndrome (FMS) is a chronic disease of widespread and debilitating pain. The cause of FMS is unknown and its risk factors are poorly understood. It occurs frequently in the general population where it is often co-morbid with other rheumatoid and pain disorders, and psychiatric disorders such as anxiety and depression, making diagnosis particularly difficult. Several types of drugs are used to treat FMS, but none are specifically approved for this indication. FMS appears to be strongly associated with depression or at least with some symptoms of depression, and antidepressants appear to be effective in the treatment of this disorder. The advent of new classes of antidepressants with fewer side effects than older drugs has suggested new avenues of therapy for patients diagnosed with FMS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12861471

Source DB:  PubMed          Journal:  IDrugs        ISSN: 1369-7056


  2 in total

1.  In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran.

Authors:  Kazuyoshi Ueta; Takahiro Suzuki; Ichiro Uchida; Takashi Mashimo
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

2.  Antidepressants in the treatment of fibromyalgia.

Authors:  Chantal Moret; Mike Briley
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.